Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

1. Does treatment guided by exhaled nitric oxide fraction improve outcomes in subgroups of children with asthma?

Does treatment guided by exhaled nitric oxide fraction improve outcomes in subgroups of children with asthma? Does Treatment Guided by Exhaled Nitric Oxide Fraction Improve Outcomes in Subgroups of Children With Asthma? - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Eur Respir J Actions . 2020 May 21;55(5):1901879. doi: 10.1183/13993003.01879-2019. Print 2020 May. Does Treatment Guided by Exhaled Nitric Oxide Fraction Improve Outcomes in Subgroups of Children With Asthma? , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Medical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. 2 Dept of Paediatric Respiratory Medicine

2020 EvidenceUpdates

2. Characteristics of Existing Asthma Self-Management Education Packages

Characteristics of Existing Asthma Self-Management Education Packages Characteristics of Existing Asthma Self-Management Education Packages Technical Brief Number 35 RTechnical Brief Number 35 Characteristics of Existing Asthma Self-Management Education Packages Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00005-I Prepared by: ECRI Institute – Penn Medicine Evidence (...) -based Practice Center Philadelphia, PA Investigators: Brian F. Leas, M.S., M.A. Kelley Tipton, M.P.H. Tyra Bryant-Stephens, M.D. Michelle Jackson-Ware, R.N., B.S.N. Nikhil Mull, M.D. Amy Y. Tsou, M.D., M.Sc. AHRQ Publication No. 20-EHC008 April 2020 ii Key Messages Purpose To identify the components that comprise asthma self-management education (AS-ME) packages used in the United States, and examine, compare, and organize their key characteristics and available research to enable a better

2020 Effective Health Care Program (AHRQ)

3. Do Antibiotics Improve Outcomes in Patients With Acute Asthma Exacerbations? Full Text available with Trip Pro

adverse events was of low quality, with very few events (10 total) reported overall. Mortality was not reported in any of the studies. There was low statistical heterogeneity between the studies for each of the outcomes reported ( I 2 =0). Commentary Asthma is a chronic respiratory condition that results in constriction of the airways because of inflammation and excess mucus production. Asthmatic patients typically have wheezing caused by narrowed airways, and symptoms are usually controlled (...) Do Antibiotics Improve Outcomes in Patients With Acute Asthma Exacerbations? Do Antibiotics Improve Outcomes in Patients With Acute Asthma Exacerbations? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Access provided by Volume 74, Issue 5, Pages 711–712 Do Antibiotics Improve Outcomes in Patients With Acute Asthma Exacerbations? x Latha Ganti , MD, MBA (EBEM Commentator) , x Javier Rosario , MD (EBEM Commentator) Department

2020 Annals of Emergency Medicine Systematic Review Snapshots

4. Advice for Healthcare Professionals Treating People with Asthma (adults) in relation to COVID-19

Advice for Healthcare Professionals Treating People with Asthma (adults) in relation to COVID-19 1 Version 4.0 7/4/20 Advice for Healthcare Professionals Treating People with Asthma (adults) in relation to COVID-19 What can I suggest my patients do to keep themselves healthy? For people with asthma, the best way of staying healthy and recovering if infected with COVID-19 is to ensure their asthma is as stable as possible. This means taking inhaled steroids and other routine medications (...) regularly, as prescribed and detailed in their personal asthma action plan. Having a reliever inhaler is also important if asthma worsens. Ensuring people have had their inhaler technique checked recently is important and you can share this website: https://www.asthma.org.uk/advice/inhaler-videos/ Advise patients to ensure they have a sufficient supply of their medication at home and order them in plenty of time to ensure they do not run out. Emphasise that they do not need to over order/ stock up

2020 British Thoracic Society

5. Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme Full Text available with Trip Pro

Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme Overuse of Short-Acting β 2-agonists in Asthma Is Associated With Increased Risk of Exacerbation and Mortality: A Nationwide Cohort Study of the Global SABINA Programme - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Eur Respir J Actions . 2020 Apr 16;55(4):1901872. doi: 10.1183/13993003.01872-2019. Print 2020 Apr. Overuse of Short-Acting β 2 -agonists in Asthma Is Associated With Increased Risk of Exacerbation and Mortality: A Nationwide Cohort Study of the Global SABINA Programme , , , , , Affiliations Expand Affiliations 1 Krefting Research Centre, Institute of Medicine, University

2020 EvidenceUpdates

6. Asthma and children: diagnosis and treatment

Asthma and children: diagnosis and treatment Asthma and children: diagnosis and treatment - NPS MedicineWise Log In Menu During the COVID-19 pandemic, you need to continue to take your usual medicines and stay as healthy as possible. Here is some important information for everyone to keep in mind. Featured topics 30 Mar 2020 30 Mar 2020 30 Mar 2020 Featured article Information for consumers about medicines and COVID-19 | Updated regularly as the situation changes. Keep a medicines list The more (...) February 2020 8 January 2020 Featured topic 20 years of helping Australians make better decisions about medicines, medical tests and other health technologies Partner with us Latest projects Search Search Search Search POPULAR Log in Log in All fields are required Email address* Password* Log in Asthma and children: diagnosis and treatment Asthma is a chronic disease that requires accurate diagnosis, regular treatment and review. For consumers , check out Asthma diagnosis and treatment during the COVID

2020 National Prescribing Service Limited (Australia)

7. Impact of Community Health Worker Certification on Workforce and Service Delivery for Asthma and Other Selected Chronic Diseases

Impact of Community Health Worker Certification on Workforce and Service Delivery for Asthma and Other Selected Chronic Diseases Impact of Community Health Worker Certification on Workforce and Service Delivery for Asthma and Other Selected Chronic Diseases Technical Brief Number 34 RTechnical Brief Number 34 Impact of Community Health Worker Certification on Workforce and Service Delivery for Asthma and Other Selected Chronic Diseases Prepared for: Agency for Healthcare Research and Quality (...) -EF March 2020 ii Key Messages Purpose of Technical Brief To explore and describe the state of the evidence on community health worker certification and its relationship with community health worker outcomes (such as recruitment, retention, and employment stability) and outcomes for people with asthma and other selected chronic illnesses. Key messages • A number of States are initiating efforts to certify community health workers practicing in their States. • We did not find any studies evaluating

2020 Effective Health Care Program (AHRQ)

8. Budesonide / formoterol fumarate dihydrate - asthma

Budesonide / formoterol fumarate dihydrate - asthma Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/118969/2020 EMEA/H/C/004882 Budesonide/Formoterol Teva Pharma B.V (...) . (budesonide/ formoterol) An overview of Budesonide/Formoterol Teva Pharma B.V. and why it is authorised in the EU What is Budesonide/Formoterol Teva Pharma B.V. and what is it used for? Budesonide/Formoterol Teva Pharma B.V. is a medicine used for the treatment of asthma in adults for whom a combination product is considered appropriate. It can be used in patients: • whose disease is not adequately controlled by treatment with other asthma medicines called corticosteroids and ‘short-acting beta-2 agonists

2020 European Medicines Agency - EPARs

9. Addressing therapeutic questions to help Canadian physicians optimize asthma management for their patients during the Covid-19 pandemic

Addressing therapeutic questions to help Canadian physicians optimize asthma management for their patients during the Covid-19 pandemic 1 ‘In Press’. Submitted for publication in the CJRCCSM on April 7, 2020. POSITION STATEMENT FROM THE CANADIAN THORACIC SOCIETY (CTS) ASTHMA ASSEMBLY STEERING COMMITTEE ADDRESSING THERAPEUTIC QUESTIONS TO HELP CANADIAN PHYSICIANS OPTIMIZE ASTHMA MANAGEMENT FOR THEIR PATIENTS DURING THE COVID-19 PANDEMIC Christopher Licskai a , Connie L. Yang b , Francine M (...) et de Pneumologie de Québec, Laval University, Québec, Québec, Canada; i Deparment of Medicine, Royal Victoria Regional Health Centre, Barrie, Ontario, Canada; j Department of Medicine, Queen’s University, Kingston, Ontario, Canada. Version 1.0 – April 7, 2020 This position statement aims to provide rapid guidance for Canadian physicians treating patients with asthma during the COVID-19 pandemic. The recommendations are informed by a very limited body of direct published data, inference from

2020 Canadian Thoracic Society

10. Targeting treatable traits in severe asthma: a randomised controlled trial

Targeting treatable traits in severe asthma: a randomised controlled trial Targeting Treatable Traits in Severe Asthma: A Randomised Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S. National Library of Medicine National Center (...) Mar 5;55(3):1901509. doi: 10.1183/13993003.01509-2019. Print 2020 Mar. Targeting Treatable Traits in Severe Asthma: A Randomised Controlled Trial , , , , , Affiliations Expand Affiliations 1 National Health and Medical Research Council, Centre of Excellence in Severe Asthma, Newcastle, Australia Vanessa.McDonald@newcastle.edu.au. 2 Priority Research Centre for Healthy Lungs, The University of Newcastle, Newcastle, Australia. 3 Hunter Medical Research Institute, Newcastle, Australia. 4 Dept

2020 EvidenceUpdates

11. Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction. (Abstract)

Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction. We previously reported the results of a trial of prenatal vitamin D supplementation to prevent asthma and recurrent wheeze in young children, which suggested that supplementation provided a protective effect at the age of 3 years. We followed the children through the age of 6 years to determine the course of asthma and recurrent wheeze.In this follow-up study, investigators and participants remained unaware (...) of the treatment assignments through the children's sixth birthday. We aimed to determine whether, when maternal levels of 25-hydroxyvitamin D were taken into account, children born to mothers who had received 4400 IU of vitamin D3 per day during pregnancy (vitamin D group) would have a lower incidence of asthma and recurrent wheeze at the age of 6 years than would those born to mothers who had received 400 IU of vitamin D3 per day (control group). Time-to-event methods were used to compare the treatment

2020 NEJM

12. Asthma: School-Based Self-Management Interventions for Children and Adolescents with Asthma

Asthma: School-Based Self-Management Interventions for Children and Adolescents with Asthma Asthma: School-Based Self-Management | The Community Guide Welcome to The Community Guide! Let us know what you think of the website by completing this . Open Navigation or Search form Search Search The Community Guide You are here » Systematic Review Topic Recommended (strong evidence) July 2019 Audience Adolescents and Young Adults Children/Infants Setting School Strategy Case Management Counseling (...) Health Education Organizational Changes This webpage summarizes information available in the CPSTF Finding and Rationale Statement. Asthma: School-Based Self-Management Interventions for Children and Adolescents with Asthma Tabs Snapshot Summary of CPSTF Finding The school-based asthma self-management interventions to reduce hospitalizations and emergency room visits among children and adolescents with asthma. Evidence shows interventions are effective when delivered by trained school staff, nurses

2020 Community Preventive Services Task Force

13. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. (Abstract)

Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. Asthma is a disease of reversible airflow obstruction characterised clinically by wheezing, shortness of breath, and coughing. Increases in airway type 2 cytokine activity, including interleukin-4 (IL-4), IL-5, and IL-13, are now established biological mechanisms in asthma. Inhaled corticosteroids have been the foundation for asthma treatment, in a large part because they decrease airway type 2 inflammation (...) . However, inhaled or systemic corticosteroids are ineffective treatments in many patients with asthma and few treatment options exist for patients with steroid resistant asthma. Although mechanisms for corticosteroid refractory asthma are likely to be numerous, the development of a new class of biologic agents that target airway type 2 inflammation has provided a new model for treating some patients with corticosteroid refractory asthma. The objective of this Therapeutic paper is to summarise the new

2020 Lancet

14. Using Inhaled Steroids in Asthma durIng the COVID-19 Outbreak Full Text available with Trip Pro

Using Inhaled Steroids in Asthma durIng the COVID-19 Outbreak Inhaled Steroids in Asthma durIng the COVID-19 Outbreak - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Inhaled Steroids in Asthma durIng the COVID-19 Outbreak Jamie Hartmann-Boyce, Richard Hobbs Are inhaled steroids in asthma OK to use or should you discontinue them? Verdict : There is no evidence of a relationship between the use of inhaled (...) corticosteroids and COVID-19 infection at present. Inhaled corticosteroids are generally considered a for controlling asthma symptoms. Evidence from a of seven randomized controlled trials found that discontinuing inhaled corticosteroids in people with stable asthma more than doubled the risk of asthma exacerbation (RR 2.35, 95% CI 1.88 to 2.92, mean follow-up 27 weeks). Inhaled corticosteroids, when taken as prescribed, would reduce the risk of an asthma attack being triggered by a respiratory virus

2020 Oxford COVID-19 Evidence Service

15. Paediatric asthma and COVID-19

Paediatric asthma and COVID-19 Paediatric asthma and COVID-19Paediatric asthma and COVID-19 | Canadian Paediatric Society A home for paediatricians. A voice for children and youth. Current: Paediatric asthma and… Practice Point Paediatric asthma and COVID-19 Posted: Apr 1 2020 The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our . Principal author(s) Elissa Abrams, Geert (...) ’t Jong, Connie Yang, Canadian Paediatric Society, , , COVID-19 is a predominantly respiratory infection, and there are concerns regarding the effects of this virus on children and youth with asthma. No evidence to date suggests that young people with asthma are at increased risk for COVID-19 infection [ ] [ ] . However, there is a theoretical possibility that a child or youth with asthma infected with COVID-19 could experience an asthma exacerbation and serious morbidity due to combined effects

2020 Canadian Paediatric Society

16. COVID-19 rapid guideline: severe asthma

COVID-19 rapid guideline: severe asthma COVID-19 rapid guideline: severe asthma NICE guideline Published: 3 April 2020 www.nice.org.uk/guidance/ng166 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals (...) and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. COVID-19 rapid guideline: severe asthma (NG166) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 11Contents Contents Overview 4 1 Communicating with patients and minimising risk 5 2 Investigations 7 3 Treatment 8

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

17. Asthma and COVID-19: risks and management considerations

Asthma and COVID-19: risks and management considerations Asthma and COVID-19: risks and management considerations - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Asthma and COVID-19: risks and management considerations May 28, 2020 Jamie Hartmann-Boyce 1 Afolarin Otunla 2 Jonny Drake 2 Jana Suklan 3 Ella Schofield 2 Jade Kinton 2 James Gunnell 2 Andrew Menzies-Gow 4 Matt Inada-Kim 5 Richard Hobbs 1 (...) if people with asthma are at increased risk of contracting COVID-19 or of worse outcomes from COVID-19 infection. The evidence available is limited with some sources suggesting an underrepresentation of PWA in hospitalised cases, and others showing an increased risk of worse outcomes in PWA which may be associated with disease severity. Consensus broadly holds that asthma medications should be continued as usual. Asthma care may be disrupted during the pandemic; self-management and remote interventions

2020 Oxford COVID-19 Evidence Service

18. Child and Adolescent Asthma Guidelines

Child and Adolescent Asthma Guidelines 10 NZMJ 1 December 2017, Vol 130 No 1466 ISSN 1175-8716 © NZMA www.nzma.org.nz/journal Asthma and Respiratory Foundation NZ child and adolescent asthma guidelines: a quick reference guide Innes Asher, David McNamara, Cheryl Davies, Teresa Demetriou, Theresa Fleming, Matire Harwood, Lorraine Hetaraka-Stevens, Tristram Ingham, John Kristiansen, Jim Reid, Debbie Rickard, Debbie Ryan ABSTRACT The purpose of the New Zealand Child and adolescent asthma (...) guidelines: a quick reference guide is to provide simple, practical, evidence-based recommendations for the diagnosis, assessment and management of asthma in children and adolescents in New Zealand, with the aim of improving outcomes and reducing inequities. The intended users are health professionals responsible for delivering asthma care in the community and hospital emergency department settings, and those responsible for the training of such health professionals. Abbreviations: FEV 1 Forced

2020 Asthma and Respiratory Foundation NZ

19. Are the 2019 Global Initiative for Asthma (GINA) strategy recommendations applicable to the Canadian context?

Are the 2019 Global Initiative for Asthma (GINA) strategy recommendations applicable to the Canadian context? Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ucts20 Canadian Journal of Respiratory, Critical Care, and Sleep Medicine Revue canadienne des soins respiratoires et critiques et de la médecine du sommeil ISSN: 2474-5332 (Print) 2474-5340 (Online) Journal homepage: https://www.tandfonline.com/loi/ucts20 (...) Are the 2019 Global Initiative for Asthma (GINA) strategy recommendations applicable to the Canadian context? Christopher Licskai, Connie L. Yang, Catherine Lemiere, Francine M. Ducharme, M. Diane Lougheed, Dhenuka Radhakrishnan, Delanya Podgers, Clare Ramsey, Tania Samanta, Andréanne Côté, Cristina Villa-Roel, Anne Van Dam & Helen Reddel To cite this article: Christopher Licskai, Connie L. Yang, Catherine Lemiere, Francine M. Ducharme, M. Diane Lougheed, Dhenuka Radhakrishnan, Delanya Podgers, Clare

2019 Canadian Thoracic Society

20. Clinical effect on uncontrolled asthma using a novel digital automated self-management solution: a physician-blinded randomised controlled crossover trial (Abstract)

Clinical effect on uncontrolled asthma using a novel digital automated self-management solution: a physician-blinded randomised controlled crossover trial AsthmaTuner is a novel self-management system consisting of a patient app, a cloud-based storage solution and a healthcare interface. Patients use Bluetooth spirometers to measure lung function (forced expiratory volume in 1 s) and can register symptoms. They then receive immediate feedback on asthma control and an image of the correct (...) inhaler(s) to use and the dose. The aim of this pilot study was to evaluate the effect of AsthmaTuner on symptom control and adherence compared with conventional treatment.This multicentre physician-blinded crossover trial randomised patients in two groups that started with 8 weeks of AsthmaTuner or conventional treatment using a personalised printed treatment plan, with 2 weeks of washout between the crossover treatments. Participants in a primary or paediatric care setting in Sweden with asthma

2019 EvidenceUpdates